Home About us Editorial board Ahead of print Browse Articles Search Submit article Instructions Subscribe Contacts Login 
  • Users Online: 124
  • Home
  • Print this page
  • Email this page


 
Previous article Browse articles Next article 
LETTER TO EDITOR
J Res Med Sci 2019,  24:4

Losartan risk for female in cisplatin-induced nephrotoxicity


1 Water and Electrolytes Research Center; Department of Physiology; IsfahanMN Institute of Basic and Applied Sciences Research, Isfahan University of Medical Sciences, Isfahan, Iran
2 Water and Electrolytes Research Center; Department of Internal Medicine, Hematology and Medical Oncology Section, Isfahan University of Medical Sciences, Isfahan, Iran

Date of Web Publication31-Jan-2019

Correspondence Address:
Mehdi Nematbakhsh
Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1735-1995.251202

Rights and Permissions

How to cite this article:
Nematbakhsh M, Ashrafi F. Losartan risk for female in cisplatin-induced nephrotoxicity. J Res Med Sci 2019;24:4

How to cite this URL:
Nematbakhsh M, Ashrafi F. Losartan risk for female in cisplatin-induced nephrotoxicity. J Res Med Sci [serial online] 2019 [cited 2019 Dec 13];24:4. Available from: http://www.jmsjournal.net/text.asp?2019/24/1/4/251202



Sir,

Blood pressure alteration and angiotensin receptor blocker treatment may influence cisplatin-induced nephrotoxicity. Komaki et al.[1] in their cohort study concluded that “Lower blood pressure and the use of renin-angiotensin system inhibitors were associated with the incidence of cisplatin nephrotoxicity” while Liu et al.[2] in their study mentioned that “Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker usage and administration of a single application of cisplatin were independent risk factors for cisplatin-induced acute kidney injury in the elderly.”

Losartan, an angiotensin II Type 1 receptor antagonist is an antihypertensive drug which is also produced antioxidant effects. According to laboratory findings, one of the benefits of losartan is the prevention of cisplatin-induced nephrotoxicity,[3],[4] but, the role of gender in the effectiveness of this drug is less pronounced while the cisplatin-induced nephrotoxicity is gender related.[5] The in vivo studies indicated that angiotensin II Type 1 receptor antagonist protected the kidney against cisplatin-induced nephrotoxicity in male gender; however, this protective role was failed in female gender.[5] The unpublished data in our laboratory, as well as our previous findings,[5] showed that losartan not only does not have a positive effect on the prevention of cisplatin-induced nephrotoxicity but also it does increase the kidney damage. The mechanism is not fully understood and needs to be defined.

Now, there is a clinical comment or suggestion. With the widespread use of angiotensin receptor blockers in female hypertensive patients; however, some of them have cancer at the same time, and they are candidate for cisplatin therapy. Therefore to prevent/to decrease the cisplatin-induced nephrotoxicity, discontinuation of angiotensin receptor blockers before cisplatin therapy in female might be recommended. In other nephrotoxic agents such as contrast, angiotensin receptor blockers have been known as an agent that increase nephrotoxicity, and in these situations, discontinuation of angiotensin receptor blockers 24–48 h before contrast administration is recommended.[1],[6] As a conclusion, it seems that in the condition of losartan and cisplatin treatments simultaneously, females are more at risk.

Financial support and sponsorship

Isfahan University of Medical Science.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Komaki K, Kusaba T, Tanaka M, Kado H, Shiotsu Y, Matsui M, et al. Lower blood pressure and risk of cisplatin nephrotoxicity: A retrospective cohort study. BMC Cancer 2017;17:144.  Back to cited text no. 1
    
2.
Liu JQ, Cai GY, Wang SY, Song YH, Xia YY, Liang S, et al. The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly. Ther Clin Risk Manag 2018;14:1279-85.  Back to cited text no. 2
    
3.
Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 2009;55:399-406.  Back to cited text no. 3
    
4.
Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H, Mortazavi M, et al. Administration of Vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol 2012;25:410-7.  Back to cited text no. 4
    
5.
Nematbakhsh M, Pezeshki Z, Eshraghi Jazi F, Mazaheri B, Moeini M, Safari T, et al. Cisplatin-induced nephrotoxicity; protective supplements and gender differences Asian Pac J Cancer Prev 2017;18:295-314.  Back to cited text no. 5
    
6.
Onuigbo MA, Onuigbo NT. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month mayo clinic study. Ren Fail 2008;30:67-72.  Back to cited text no. 6
    




 

Top
Previous article  Next article
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed839    
    Printed41    
    Emailed0    
    PDF Downloaded136    
    Comments [Add]    

Recommend this journal